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Background: Behavioral disturbances following chemotherapy with cisplatin are rare. Here, we report a patient
with temporary loss of moral behavior in the setting of cisplatin-based chemotherapy for treatment of tonsillar cancer.
Case presentation: A 66-year-old Caucasian male with no psychiatric or violent history was started on chemotherapy
with cisplatin for treatment of tonsillar cancer. During the following weeks, the patient developed profound personality
changes involving volatile emotions and impulsive aggression with verbal and physical assaults on others. Admitted to
the hospital, the patient lacked any awareness that his behavior was wrong. Chemotherapy was discontinued and the
patient was prescribed risperidone. Aside from mild cognitive impairment, comprehensive neuropsychological,
neuroradiological and lab testing were unremarkable. Three weeks following cessation of chemotherapy, the patient
had recovered to his original mental state and he was completely aware of his wrongdoing and social misconduct.
Conclusion: Since neurotoxic effects of chemotherapeutics on the brain are not yet sufficiently elucidated, our case
emphasizes that early signs of behavioral abnormalities in patients receiving chemotherapy should trigger
comprehensive psychiatric evaluation and ongoing monitoring of the patients’ mental state.Background
Abnormal moral behavior resulting in social inappropri-
ateness and aggressive conduct has been described as a
result of structural damage to the frontal lobe of the
brain [1-3]. We report on a patient with temporary loss
of moral behavior with severe aggressive and violent out-
bursts in the setting of cisplatin-based chemotherapy for
treatment of tonsillar cancer.
Case presentation
A 66-year-old Caucasian male underwent curative tonsil-
lectomy and ipsilateral radical neck dissection for right-
sided tonsillar cancer (T2, N2b, cM0, G2; stage IVa). Four
weeks after surgery, he was started on combined radiation
therapy at a total dose of 60 Gy to the neck and chemo-
therapy with cisplatin (with standard schedule of 6 cycles
á 40 mg/m2 = 73 mg, weekly).* Correspondence: kristian.barlinn@uniklinikum-dresden.de
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unless otherwise stated.During the following three weeks, the patient’s wife in-
creasingly observed changes in her husband’s personality
involving irritability, volatile emotions and impulsive ag-
gression leading to verbal abuse and threats towards
family members and neighbors (e.g., he delivered a letter
to his neighbor including strong abusive language). The
patient started to argue with his neighbor about propri-
etary rights of a water pump that has been shared for a
long time. Ultimately he revealed physical aggression
while cutting through the pipes of the water pump and
chopping the house’s windowsills using an axe. After the
fourth cycle of chemotherapy was completed, the situ-
ation escalated at home as his wife wanted to restrain
him from driving his car after he had expressed suicidal
thoughts in a state of agitation. He threatened to push
her down the stairs unless she was willing to hand over
the car keys. Finally their daughter called the police and
emergency medical services and the patient was pre-
sented to the emergency department.
On initial mental state examination, the patient articu-
lated himself clearly and was oriented to person, place
and time. Initial testing of global cognitive functions didThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and placid throughout the interview. When questioned
about the preceding events, he trivialized them and re-
vealed lack of any understanding that his behavior was
wrong. Instead, he blamed his wife being responsible for
his current situation and assured the admitting psych-
iatrist that he would avenge himself by giving his wife a
sound beating once at home. His affect was euthymic
with normal emotional reactivity while being inappropri-
ate to the situation. The patient’s thought process and
content were unremarkable. He denied any current sui-
cidal ideation. Eventually he accepted admission to the
acute psychiatric ward; however, he stated that his mo-
tivation was primarily the fact that this would spare him
the daily drive to the hospital to receive ambulatory
radiotherapy.
The patient did not have any other past medical or psy-
chiatric history. He reported a history of chronic alcohol
consumption (about two large beer per day), which he had
ended after the diagnosis of tonsillar cancer 3 months ago
with no occurrence of alcohol withdrawal symptoms.
Drug history was insignificant. His wife assured that he
had never been a violent or aggressive person in 42 years
of marriage and that the current behavior was radically
different. Brain contrast-enhanced computed tomography
on admission revealed no significant findings. No abnor-
mal findings were apparent on routine blood test (includ-
ing blood alcohol level).
At first, the patient behaved cooperatively on the ward.
The next day, however, he felt harassed by the volume of
a fellow patient’s radio, so he angrily walked into the fel-
low patient’s room, intentionally destroyed the radio and
assaulted her with his shoes and fists. He also attacked
an attending nurse who came to intervene with his fists.
Subsequently, the patient was restrained and, with ob-
tained consent of the patient, intravenously treated with
lorazepam. Further hospitalization commitment was or-
dered by court due to endangerment of others. Like the
previous day, the patient appeared unrepentant and
lacked any awareness of wrongdoing. Rather, he tried to
rationalize his violent behavior by stressing that everyone
feeling disturbed would have acted this way. The patient
was started on neuroleptic treatment with risperidone
0.5 mg twice daily and lorazepam temporarily. The
remaining two cycles of chemotherapy were not com-
pleted due to the unpredictability of the patient’s behavior;
radiation therapy was continued as scheduled.
In the following, magnetic resonance imaging of the
head showed a minor degree of general brain atrophy
and slight chronic microvascular white matter changes.
Cerebrospinal fluid examination including tests for infec-
tious diseases (e.g., neurosyphilis) and biomarkers for
Alzheimer’s Disease was unremarkable. No abnormal
values were found on comprehensive blood tests includingthyroid hormones and B vitamins. Although the patient
scored within the normal range on both mini-mental state
examination (MMSE, 28 points) and DemTect (16 points),
the three-item clock-drawing test (CDT, 3 points) and
Nuremberg Age Inventory (NAI) revealed a slight im-
pairment in executive cognition. Specifically, he scored
slightly below average in the NAI Labyrinth-, Number-
and Word- Connection items (78, 83 and 84 points,
respectively).
Over the course of the patient’s stay, the psychopatho-
logical condition improved constantly. Although still con-
vinced that his conduct was justified, he was on good
terms with the hospital staff and his fellow patients and
increasingly behaved cooperatively and adequately. There-
fore, the patient was put on home visit for stress vacation
without any incidents and three weeks following cessation
of cisplatin therapy, the patient’s wife confirmed that he
had recovered to his original mental state. By that time,
the patient was aware of his wrongdoing and regretted his
recent social misconduct. He further emphasized that
such conduct was not consistent with his personality. Of
note, the patient did not experience any amnesia over the
reported course. The patient was discharged four weeks
after admission with continuation of risperidone and fur-
ther treated by an ambulatory psychiatrist.
Discussion
In this case report, a loss of moral behavior was noticed
that was not related to an established psychiatric disorder
or structural brain damage but occurred in temporal prox-
imity to cisplatin-based chemotherapeutic treatment of
tonsillar cancer. Discontinuation of chemotherapy and
start of neuroleptic treatment may have reversed the
patient’s psychopathological condition. Hence, our case
highlights the importance of pharmacovigilance in chemo-
therapy with regard to psychiatric symptoms as these may
affect compliance to treatment and, thus, long-term
prognosis.
Recent reports have attributed certain encephalopathy
syndromes (e.g., the posterior reversible encephalopathy
syndrome) to cisplatin or carboplatin therapy causing
severe neurological complications [4]; however, sole
psychiatric disturbances following platinum-based chemo-
therapy seem rare. Since the introduction of platinum-
based drugs in the 1970s for treatment of various types of
cancer [5], only a few cases of new-onset psychotic or
manic episodes were reported during treatment with
platinum-based antineoplastic drugs [6-8].
The set of behavioral disturbances observed in our
patient, namely disinhibition, impulsivity, inappropriate
affect, emotional lability and poor judgment and insight
was highly suggestive of a dysexecutive syndrome [1]. Al-
though this syndrome has been formerly referred to as
frontal lobe syndrome as dysexecutive symptoms are
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age, research studies demonstrated that it may also
involve cortical and subcortical regions outside the
frontal lobe [1-3].
Neurological causes of dysexecutive syndrome com-
prise stroke, multiple sclerosis, tumor and dementia with
permanent structural damages to the frontal lobe [1]. Al-
though our patient did not show gross cognitive deficits
indicated by standard neuropsychological testing, more
in-depth tests (such as the three-item CDT and NAI) re-
vealed slight impairment in executive cognition suggest-
ive of mild cognitive impairment, which is commonly
seen in, but not specific for, dysexecutive syndrome [9].
However, as changes in moral behavior are also fre-
quently seen in mania, a manic episode was considered
a differential diagnosis. In disconcordance with this dif-
ferential, current psychopathology did not fulfill formal
diagnostic criteria for an acute manic episode and his-
tory taken from our patient and his wife did not reveal
any previous depressive or hypomanic/manic episodes
[10]. Although we did not perform a specific test, an
antisocial personality disorder or antisocial trait was not
deemed likely either since the patient’s history did not
reveal any corresponding symptoms prior to the treat-
ment with cisplatin.
Alternatively, the patient’s behavioral disturbances might
be explained by early dementia. After initial diagnosis of
dementia, older patients are at an almost 10-times higher
risk of developing a manic-like episode than older patients
without dementia [11]. Conversely, mild cognitive impair-
ment detected in our patient might be an early state of
Alzheimer’s disease or other types of dementia and might
therefore, pathomechanistically, constitute an synergism
with cisplatin induced predominant frontal cerebral dys-
function leading to behavioral disturbances observed in
this case [12]. This synergistic mechanism is also consist-
ent with the previous observation that patients with
higher cognitive reserves are able to compensate cognitive
declining but this compensation can be compromised by
exogenic noxa to the brain such as physical illness or cer-
tain drugs [13,14]. This noxa-induced decompensation of
cognitive function in patients with subclinical dementia
can be reversed by ending noxa exposition which is con-
sistent with the return to normal behavior following cessa-
tion of cisplatin therapy in our patient [15].
Also, the presence of a synergistic pathomechanism with
functional cerebral damage due to cisplatin therapy and
preceding subclinical dementia in our patient might be
consistent with the lack of reported cases of dysexecutive
syndrome in cisplatin treated patients. However, mild cog-
nitive impairment in our patient might have also resulted
from chronic alcohol abuse (the latter in accordance with
normal cerebrospinal fluid Alzheimer’s markers). Since
the patient received radiotherapy treatment solely to theneck area with safety margins applied to spare surround-
ing, inter alia, brain tissues, we did not consider radiother-
apy being related to the psychiatric outbreak in this case.
This is underlined by the fact that radiation therapy was
continued during hospitalization yet the patient improved
constantly.
While peripheral sensory neurotoxicity mediated by
DNA-cross links with positive charged molecules formed
by hydrolytic aquation in dorsal root ganglion neurons is a
common side effect of platinum-based antineoplastic
drugs affecting almost one in two treated patients, cyto-
toxic effects of cisplatin to the central nervous system are
not well elucidated [16,17]. One explanation for this ap-
parent relative sparing of the central nervous system
might be the characteristics of the compartmental distri-
bution of the drug in vivo. In a study in 11 patients with
ovarian cancer receiving cisplatin, the investigators ob-
served equally high platinum concentrations in tumor,
sural nerves, and spinal ganglia, but substantially lower
platinum concentration in brain [18]. This loss of plat-
inum on its way to the central nervous system might be
caused by the reduced capacity of positive charged
molecules formed by cisplatin aquation to cross the
blood–brain barrier. Concordantly, following osmotic
blood–brain barrier modification in an experimental
setting in dogs, cisplatin was shown to induce dissemi-
nated cerebral foci of hemorrhagic necrosis and edema
[19]. However, these focal lesions were also observed in
other chemotherapeutic agents such as 5-fluorouracil and
adriamycin and could therefore not be linked to a drug-
specific pharmacodynamic mechanism.
While blood–brain-barrier induced peripheral-central
concentration gradient of cisplatin in vivo might, in parts,
explain the discrepancy of highly prevalent cisplatin in-
duced peripheral nerve damage and low prevalent central
adverse effects of cisplatin, it does not explain the oc-
currence of selective dysexecutive symptoms (with pre-
dominant frontal lobe pathology) following cisplatin
administration as reported in this case. Our observa-
tion, viewed in conjunction with the current literature,
might therefore suggest the possibility of an alternative
coincident mechanism of cisplatin which causes predom-
inant frontal cerebral neuron dysfunction in humans if
the blood–brain-barrier has been passed to sufficient
extent.Conclusion
Since neurotoxic effects of chemotherapeutics on the
brain are not yet sufficiently elucidated, our case empha-
sizes that early signs of behavioral changes in patients
receiving chemotherapy should trigger comprehensive
psychiatric evaluation and ongoing monitoring of the pa-
tients’ mental state.
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